TIDMAGL
RNS Number : 1763N
Angle PLC
19 January 2023
For immediate release 19 January 2023
ANGLE plc ("the Company")
APPOINTMENT OF NON-EXECUTIVE DIRECTOR
Joseph Eid M.D., is a US certified medical oncologist with
extensive experience of the use of biomarkers in clinical trials
and as companion diagnostics
Previous roles include senior positions in oncology at Bristol
Myers Squibb, Merck & Co. and Hoffman-La Roche
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is delighted to announce that Joseph (Joe) Eid M.D. has
been appointed as a Non-Executive Director of the Company, with
effect from 19 January 2023.
Joe is a qualified physician, board certified in medical
oncology, haematology, and internal medicine. He is a highly
experienced pharmaceutical industry executive with over 25 years of
proven expertise in people and portfolio management, planning,
designing, and executing Phase I to IV clinical trials and building
and managing clinical and medical affairs teams and strategies. He
has successfully designed and implemented clinical development,
medical affairs, and life cycle management plans for pharmaceutical
products including cytotoxic agents, monoclonal antibodies,
immuno-oncology agents, antibody-drug conjugates, and CAR-T Cell
therapies.
Joe most recently served as Chief Medical Officer and Head of
Global Drug Development for Princeton, New Jersey based Luzsana
Biotechnology (a wholly owned subsidiary of Jiangsu Hengrui
Pharmaceutical). Importantly, his previous experience includes
senior positions in clinical development and medical affairs at
Bristol Myers Squibb, Merck & Co. and Hoffman-La Roche.
Whilst at Merck, Joe led the global Keytruda(R) (pembrolizumab,
MK-3475) first-in-human strategy, including oversight of the
clinical, regulatory, and manufacturing planning and execution and
development of the PD-L1 biomarker strategy on tissue biopsy, which
led to a first-in-class anti-PD-1 BLA filing and approval in the
US.
Joseph Eid M.D., commented:
"I believe that ANGLE's Parsortix technology and unique liquid
biopsy approach has enormous potential both in oncology drug
development and in the clinical setting. I look forward to
leveraging my extensive experience of the development and use of
biomarkers in oncology to drive forward the Company's strategy and
to using my network of pharma industry, clinical and academic
thought leaders to accelerate the Company's commercial
development."
ANGLE Chairman, Garth Selvey, added:
"We are delighted that Joe has agreed to join the ANGLE Board.
Joe brings valuable knowledge and experience in oncology drug
development and the use of biomarkers in the clinical trials
process and as companion diagnostics. This is a key focus for the
Company's pharma services business and will be of enormous benefit
going forward."
Other than as disclosed below, there are no further disclosures
to be made in connection with Joseph Emile Eid (age 55) in
accordance with AIM Rule 17 and paragraph (g) of Schedule Two of
the AIM Rules for Companies:
Current Previous
Joseph Eid Biopharma Consulting Luzsana Biotechnology, Inc
LLC
---------------------------
Luminary Therapeutics, Inc Bristol Myers Squibb
---------------------------
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Thomas Bective, Shaam Vora +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the EU Market Abuse Regulation (596/2014) . Upon the publication of
this announcement via a regulatory information service, this
information is considered to be in the public domain.
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
circulating tumor cell (CTC) harvesting technology is known as the
Parsortix(R) system.
ANGLE's Parsortix(R) system is FDA cleared for its intended use
in metastatic breast cancer and is currently the first and only FDA
cleared medical device to harvest intact circulating cancer cells
from blood.
Intended use
The Parsortix(R) PC1 system is an in vitro diagnostic device
intended to enrich circulating tumor cells (CTCs) from peripheral
blood collected in K(2) EDTA tubes from patients diagnosed with
metastatic breast cancer. The system employs a microfluidic chamber
(a Parsortix cell separation cassette) to capture cells of a
certain size and deformability from the population of cells present
in blood. The cells retained in the cassette are harvested by the
Parsortix PC1 system for use in subsequent downstream assays. The
end user is responsible for the validation of any downstream assay.
The standalone device, as indicated, does not identify, enumerate
or characterize CTCs and cannot be used to make any
diagnostic/prognostic claims for CTCs, including monitoring
indications or as an aid in any disease management and/or treatment
decisions.
The Parsortix system enables a liquid biopsy (a simple blood
test) to be used to provide the circulating metastatic breast
cancer cells to the user in a format suitable for multiple types of
downstream analyses. The system is based on a microfluidic device
that captures cells based on a combination of their size and
compressibility. The system is epitope independent and can capture
all phenotypes of CTCs (epithelial, mesenchymal and EMTing CTCs) as
well as CTC clusters in a viable form (alive). CTCs harvested from
the system enable a complete picture of a cancer to be seen; as
being an intact cell they allow DNA, RNA and protein analysis as
well as cytological and morphological examination and may provide
comparable analysis to a tissue biopsy in metastatic breast cancer.
Because CTC analysis is a non-invasive process, unlike tissue
biopsy, it can be repeated as often as needed. This is important
because cancer develops and changes over time and there is a clear
medical need for up-to-date information on the status of a
patient's tumor. In addition, the live CTCs harvested by the
Parsortix system can be cultured, which offers the potential for
testing tumor response to drugs outside the patient.
The Parsortix technology is the subject of 26 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide.
In the United States, the Parsortix(R) PC1 system has received a
Class II Classification from FDA for use with metastatic breast
cancer patients. FDA clearance is seen as the global gold standard.
ANGLE's Parsortix system is the first ever FDA cleared system for
harvesting CTCs for subsequent analysis. ANGLE has applied the IVD
CE Mark to the same system for the same intended use in Europe.
ANGLE has also completed three separate 200 subject clinical
studies under a programme designed to develop an ovarian cancer
pelvic mass triage test, with the results showing best in class
accuracy (AUC-ROC) of 95.4% with sensitivity of 90% and specificity
of 93%. This excellent clinical result demonstrates the utility of
cells harvested by the Parsortix system, which the Company believes
is the "best sample" for liquid biopsy analysis as it recovers
intact, living cancer cells that are involved in the progression of
the disease providing prospective information.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
76 peer-reviewed publications and numerous publicly available
posters from 33 independent cancer centres, available on our
website.
ANGLE has established clinical services laboratories in the UK
and the United States to accelerate commercialisation of the
Parsortix system and act as demonstrators to support product
development. The laboratories offer services globally to
pharmaceutical and biotech customers for use of Parsortix in cancer
drug trials and, once the laboratories are accredited and tests
validated, will provide Laboratory Developed Tests (LDTs) for
patient management.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFZGMMVRLGFZM
(END) Dow Jones Newswires
January 19, 2023 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024